Observational Study of Inflammatory Arthritis Treatment by Etanercept Originator Switched to an Etanercept Biosimilar

Reumatologia- Poland

doi 10.5114/reum.2019.89516

Full Text

Abstract

Available in

Date

January 1, 2019

Authors

Anna Felis-Giemza

Kornelia Chmurzyńska

Jolanta Nałęcz-Janik

Katarzyna Romanowska-Próchnicka

Katarzyna Świerkocka

Mariusz Wudarski

Marzena Olesińska

Publisher

Termedia Sp. z.o.o.

Related search

FRI0103 One-Year Follow-Up of a Nationwide Cohort of Patients With Inflammatory Arthritis, Who Switched From Originator to Biosimilar Etanercept, Focusing on Patients Who Switched Back to Originator. An Observational Danbio Study

2018

English

GP2015: An Etanercept Biosimilar

English

SAT0199 Switch From Innovator Etanercept to Biosimilar Etanercept in Inflammatory Rheumatic Diseases: The Experience of Cochin University Hospital Paris-France.

2018

English

Switch From Reference Etanercept to SDZ ETN, an Etanercept Biosimilar, Does Not Impact Efficacy, Safety, and Immunogenicity of Etanercept in Patients With Moderate-To-Severe Rheumatoid Arthritis: 48-Week Results From the Phase III, Randomized, Double-Blind EQUIRA Study

Arthritis Research & Therapy

2019

English

Response To: ‘Mandatory, Cost-Driven Switching From Originator Etanercept to Its Biosimilar SB4: Possible Fallout on Non-Medical Switching’ by Cantini and Benucci

Annals of the Rheumatic Diseases

English

Pms70 - Biosimilar and Originator Etanercept: Influence of Local Policy Measures and Practices on Market Dynamics Between Swedish Counties

English

Evaluation of the Cost Saving Potential of Introducing an Etanercept Biosimilar (Benepali®) for the Treatment of All Licensed Adult Etanercept Indications in the UK

English

Real-World Evidence on Etanercept Biosimilar SB4 in Etanercept-Naïve or Switching Patients: A Systematic Review

Rheumatology and Therapy

2019

English

Pharmacogenetics of Etanercept in Rheumatoid Arthritis

English

Amanote Research

Observational Study of Inflammatory Arthritis Treatment by Etanercept Originator Switched to an Etanercept Biosimilar

Reumatologia- Poland

Full Text

Abstract

Categories

Date

Authors

Publisher

Related search

FRI0103 One-Year Follow-Up of a Nationwide Cohort of Patients With Inflammatory Arthritis, Who Switched From Originator to Biosimilar Etanercept, Focusing on Patients Who Switched Back to Originator. An Observational Danbio Study

GP2015: An Etanercept Biosimilar

SAT0199 Switch From Innovator Etanercept to Biosimilar Etanercept in Inflammatory Rheumatic Diseases: The Experience of Cochin University Hospital Paris-France.

Switch From Reference Etanercept to SDZ ETN, an Etanercept Biosimilar, Does Not Impact Efficacy, Safety, and Immunogenicity of Etanercept in Patients With Moderate-To-Severe Rheumatoid Arthritis: 48-Week Results From the Phase III, Randomized, Double-Blind EQUIRA Study

Response To: ‘Mandatory, Cost-Driven Switching From Originator Etanercept to Its Biosimilar SB4: Possible Fallout on Non-Medical Switching’ by Cantini and Benucci

Pms70 - Biosimilar and Originator Etanercept: Influence of Local Policy Measures and Practices on Market Dynamics Between Swedish Counties

Evaluation of the Cost Saving Potential of Introducing an Etanercept Biosimilar (Benepali®) for the Treatment of All Licensed Adult Etanercept Indications in the UK

Real-World Evidence on Etanercept Biosimilar SB4 in Etanercept-Naïve or Switching Patients: A Systematic Review

Pharmacogenetics of Etanercept in Rheumatoid Arthritis